CO2021013417A2 - Arn del replicón-lnp oncolítico sintético y usos para la inmunoterapia contra el cáncer - Google Patents
Arn del replicón-lnp oncolítico sintético y usos para la inmunoterapia contra el cáncerInfo
- Publication number
- CO2021013417A2 CO2021013417A2 CONC2021/0013417A CO2021013417A CO2021013417A2 CO 2021013417 A2 CO2021013417 A2 CO 2021013417A2 CO 2021013417 A CO2021013417 A CO 2021013417A CO 2021013417 A2 CO2021013417 A2 CO 2021013417A2
- Authority
- CO
- Colombia
- Prior art keywords
- rna
- lnp
- replicon
- cancer immunotherapy
- synthetic oncolytic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962815611P | 2019-03-08 | 2019-03-08 | |
| PCT/US2020/013069 WO2020185293A1 (en) | 2019-03-08 | 2020-01-10 | Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021013417A2 true CO2021013417A2 (es) | 2022-01-17 |
Family
ID=69526302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0013417A CO2021013417A2 (es) | 2019-03-08 | 2021-10-07 | Arn del replicón-lnp oncolítico sintético y usos para la inmunoterapia contra el cáncer |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11717548B2 (en]) |
| EP (1) | EP3934673A1 (en]) |
| JP (2) | JP7561134B2 (en]) |
| KR (1) | KR20220006041A (en]) |
| CN (1) | CN113966221A (en]) |
| AU (1) | AU2020233788A1 (en]) |
| BR (1) | BR112021017637A8 (en]) |
| CA (1) | CA3132714A1 (en]) |
| CO (1) | CO2021013417A2 (en]) |
| IL (1) | IL285963A (en]) |
| MX (1) | MX2021010808A (en]) |
| PH (1) | PH12021552145A1 (en]) |
| SG (1) | SG11202109514VA (en]) |
| WO (1) | WO2020185293A1 (en]) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020185293A1 (en) * | 2019-03-08 | 2020-09-17 | Massachusetts Institute Of Technology | Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy |
| CN113509542A (zh) * | 2021-04-20 | 2021-10-19 | 嘉晨西海(杭州)生物技术有限公司 | 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法 |
| CZ310443B6 (cs) * | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| US20250152737A1 (en) | 2022-04-26 | 2025-05-15 | Strand Therapeutics Inc. | Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof |
| CN115227674B (zh) * | 2022-08-05 | 2023-07-04 | 武汉滨会生物科技股份有限公司 | 包封的溶瘤病毒遗传物质及其应用 |
| AU2024208643A1 (en) * | 2023-01-12 | 2025-06-26 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE |
| WO2024211865A2 (en) * | 2023-04-07 | 2024-10-10 | Omega Therapeutics, Inc. | Lipids and lipid-like compounds for therapeutic lipid nanoparticle (lnp) delivery |
| CN118147171B (zh) * | 2024-03-08 | 2024-12-06 | 上海复诺健生物科技有限公司 | 具有增强的外源基因表达水平的自扩增mRNA核酸序列 |
| WO2025024704A1 (en) | 2023-07-25 | 2025-01-30 | Strand Therapeutics Inc. | Polynucleotides comprising a micro rna detargeting sensor and uses thereof |
| CN119479778B (zh) * | 2024-10-16 | 2025-04-25 | 北京悦康科创医药科技股份有限公司 | 一种lnp转染效率预测模型构建方法及装置 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP2451475A2 (en) * | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
| HRP20161352T1 (hr) * | 2010-07-06 | 2016-12-02 | Glaxosmithkline Biologicals Sa | Čestice nalik na virione za unos samoreplicirajućih molekula rna |
| EP2729168A2 (en) * | 2011-07-06 | 2014-05-14 | Novartis AG | Immunogenic compositions and uses thereof |
| WO2014089061A1 (en) * | 2012-12-03 | 2014-06-12 | Yasuko Rikihisa | Ehrlichial invasin for immunization, diagnosis, and cell delivery |
| WO2016037053A1 (en) * | 2014-09-05 | 2016-03-10 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| EP3212772A4 (en) * | 2014-10-31 | 2018-10-03 | Massachusetts Institute of Technology | Delivery of biomolecules to immune cells |
| EP3297637B1 (en) | 2015-05-21 | 2021-05-26 | Ohio State Innovation Foundation | Benzene-1,3,5-tricarboxamide derivatives and uses thereof |
| WO2020185293A1 (en) * | 2019-03-08 | 2020-09-17 | Massachusetts Institute Of Technology | Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy |
| EP4185274A1 (en) * | 2020-07-24 | 2023-05-31 | Strand Therapeutics Inc. | Lipidnanoparticle comprising modified nucleotides |
| US20240140960A1 (en) * | 2021-02-12 | 2024-05-02 | Ohio State Innovation Foundation | Sugar derived lipid nanomaterials and uses thereof |
| CN117897494A (zh) * | 2021-07-09 | 2024-04-16 | 瑞普利科特生物科学公司 | 经修饰的东方马脑炎病毒、自复制rna构建体及其用途 |
| CN117180454A (zh) * | 2022-05-16 | 2023-12-08 | 上海行深生物科技有限公司 | 含有自复制rna分子和脂质纳米颗粒递送载体的组合物及其制备方法 |
-
2020
- 2020-01-10 WO PCT/US2020/013069 patent/WO2020185293A1/en active Application Filing
- 2020-01-10 SG SG11202109514VA patent/SG11202109514VA/en unknown
- 2020-01-10 JP JP2021553767A patent/JP7561134B2/ja active Active
- 2020-01-10 CN CN202080034343.3A patent/CN113966221A/zh active Pending
- 2020-01-10 BR BR112021017637A patent/BR112021017637A8/pt unknown
- 2020-01-10 AU AU2020233788A patent/AU2020233788A1/en active Pending
- 2020-01-10 PH PH1/2021/552145A patent/PH12021552145A1/en unknown
- 2020-01-10 CA CA3132714A patent/CA3132714A1/en active Pending
- 2020-01-10 US US16/739,407 patent/US11717548B2/en active Active
- 2020-01-10 KR KR1020217032460A patent/KR20220006041A/ko active Pending
- 2020-01-10 MX MX2021010808A patent/MX2021010808A/es unknown
- 2020-01-10 EP EP20704372.0A patent/EP3934673A1/en active Pending
-
2021
- 2021-08-30 IL IL285963A patent/IL285963A/en unknown
- 2021-10-07 CO CONC2021/0013417A patent/CO2021013417A2/es unknown
-
2023
- 2023-06-14 US US18/334,449 patent/US12383589B2/en active Active
-
2024
- 2024-09-20 JP JP2024163492A patent/JP2025011109A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022524391A (ja) | 2022-05-02 |
| US20240024394A1 (en) | 2024-01-25 |
| IL285963A (en) | 2021-10-31 |
| US12383589B2 (en) | 2025-08-12 |
| JP2025011109A (ja) | 2025-01-23 |
| BR112021017637A2 (en]) | 2021-11-09 |
| CA3132714A1 (en) | 2020-09-17 |
| JP7561134B2 (ja) | 2024-10-03 |
| EP3934673A1 (en) | 2022-01-12 |
| KR20220006041A (ko) | 2022-01-14 |
| US20200281994A1 (en) | 2020-09-10 |
| AU2020233788A1 (en) | 2021-10-07 |
| MX2021010808A (es) | 2021-12-15 |
| BR112021017637A8 (pt) | 2022-08-16 |
| PH12021552145A1 (en) | 2022-08-31 |
| US11717548B2 (en) | 2023-08-08 |
| CN113966221A (zh) | 2022-01-21 |
| WO2020185293A1 (en) | 2020-09-17 |
| SG11202109514VA (en) | 2021-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021013417A2 (es) | Arn del replicón-lnp oncolítico sintético y usos para la inmunoterapia contra el cáncer | |
| MX2021008146A (es) | Polinucleotidos de arn encapsulado y metodos de uso. | |
| CY1123563T1 (el) | Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων | |
| AR118725A2 (es) | Vectores para expresión de antígenos asociados a próstata | |
| BR112019001737A2 (pt) | expressão de pten-long com vírus oncolíticos | |
| MX2016011537A (es) | Metodos y composiciones para aumentar una relacion de celulas t efectoras con respecto a las celulas t reguladoras. | |
| MX2019004913A (es) | Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm). | |
| MX2018008413A (es) | Virus oncolitico modificado. | |
| CO2017010831A2 (es) | Adenovirus oncolítico que codifica una proteína b7 | |
| UY35965A (es) | Anticuerpos humanos contra pd?l1 | |
| MX389093B (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
| MX2016016301A (es) | Procesos de siembra en serie y usos de los mismos. | |
| MX2015016627A (es) | Vacuna para la malaria. | |
| MX2016006758A (es) | Composiciones y metodos de vectores para inducir una respuesta inmunitaria mediante el uso de vectores de poxvirus. | |
| BR112015021880A2 (pt) | rearranjo de vírus influenza b | |
| MX2017011655A (es) | Compuestos de aza-piridona y usos de estos. | |
| BR112015025748A2 (pt) | construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna | |
| CU24580B1 (es) | Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas | |
| CL2021001256A1 (es) | Vacunación con el dominio alfa 3 de mica/b para el tratamiento del cáncer (divisional sol 201801470) | |
| MX2016013631A (es) | Celulas huespedes modificadas y usos de las mismas. | |
| CR20160178A (es) | Derivados de desoxinojirimicina y sus métodos de uso | |
| CO2018008288A2 (es) | Virus de la tilapia de tipo ortomixo | |
| CL2018000164A1 (es) | Vector recombinante del virus orf. | |
| UY36617A (es) | Proteínas de fusión inmunogénicas para el tratamiento del cáncer | |
| CO2018007442A2 (es) | Vacunas contra el cáncer |